![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » CORNERSTONE BIOPHARMA ACQUIRES EXTENDRYL FAMILY OF PRODUCTS FROM FLEMING & COMPANY, PHARMACEUTICALS
CORNERSTONE BIOPHARMA ACQUIRES EXTENDRYL FAMILY OF PRODUCTS FROM FLEMING & COMPANY, PHARMACEUTICALS
Cornerstone BioPharma has announced the acquisition of the Extendryl family of products from Fleming & Company, Pharmaceuticals, which occurred Jan. 1. Extendryl SR, Extendryl JR, Extendryl Chewable and Extendryl Syrup are prescription respiratory medications indicated for the relief of respiratory congestion, allergic rhinitis, and vasomotor rhinitis. Currently, 50 million Americans suffer from allergy symptoms and these symptoms often begin in childhood. These products are available in time-released capsules (in adult and pediatric formulations), chewable tablets and syrup.
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
11Jul
-
18Jul
-
21Oct